Wegovy HD (Semaglutide 7.2 mg) Guide
Novo Nordisk's High-Dose Weekly Injection for Obesity
Wegovy HD is the higher-dose 7.2 mg formulation of semaglutide — FDA-approved in March 2026 for adults who need more weight loss than the standard 2.4 mg dose delivers. In the STEP UP trial it produced 20.7% mean body weight loss over 72 weeks. Here's how it works, how it's dosed, and who it's for.
What Is Wegovy HD (Semaglutide 7.2 mg)?
Wegovy HD ("high dose") is Novo Nordisk's 7.2 mg once-weekly subcutaneous injection of semaglutide — the same GLP-1 receptor agonist as standard Wegovy, but at three times the 2.4 mg maintenance dose. The FDA approved it on March 19, 2026 for chronic weight management in adults with obesity, with a US launch in April 2026.
It is the same molecule and the same weekly injection routine most Wegovy users already know. The difference is the ceiling: where standard Wegovy maxes out at 2.4 mg, Wegovy HD continues titrating to 7.2 mg for patients who have not reached their goal or who have plateaued on the 2.4 mg dose.
Wegovy HD is positioned as a step-up option, not a starting point. Patients still begin at the low 0.25 mg dose and titrate upward to manage gastrointestinal side effects — Wegovy HD simply extends that ladder to a higher maintenance rung.
STEP UP Trial Results
How Wegovy HD Works
Titration to the 7.2 mg Maintenance Dose
Standard Wegovy starting ladder — 0.25, 0.5, then 1.0 mg, escalating roughly every 4 weeks.
Standard maintenance band. Many patients stay here; HD candidates continue up.
High-dose maintenance for those needing more loss. Titrate under prescriber guidance; do not jump straight to 7.2 mg.
Wegovy HD vs Standard Wegovy
| Feature | Wegovy (2.4 mg) | Wegovy HD (7.2 mg) |
|---|---|---|
| Active Drug | Semaglutide | Semaglutide (same molecule)Best |
| Maintenance Dose | 2.4 mg weekly | 7.2 mg weekly |
| Administration | Once-weekly SC injection | Once-weekly SC injection |
| Pivotal Trial | STEP 1: 14.9% at 68 wks | STEP UP: 20.7% at 72 wks |
| ≥25% Weight Loss | Less common | 31.2% of patients |
| Intended Use | First-line maintenance | Step-up for inadequate response / plateau |
| Titration | To 2.4 mg | Continues past 2.4 mg to 7.2 mg |
| FDA Approval | June 2021 | March 2026 |
Side Effects and Considerations
The side effect profile mirrors standard semaglutide: nausea, vomiting, diarrhea, constipation, and abdominal discomfort, mostly during titration. Because the maintenance dose is higher, GI effects can be more pronounced for some patients, which is why slow titration matters.
As with all GLP-1 therapy, lean mass loss is a consideration — a meaningful share of weight lost can be muscle. Adequate protein intake and resistance training help preserve lean mass. Wegovy HD carries the same boxed warning for thyroid C-cell tumors and is contraindicated in personal or family history of medullary thyroid carcinoma or MEN 2.
Wegovy HD is a step-up, not a shortcut. Higher dose does not mean "start higher" — it means a higher ceiling for those who need it. Work with your prescriber on whether escalating beyond 2.4 mg is appropriate for your response and tolerance.
Guide FAQs
Wegovy HD is the 7.2 mg high-dose formulation of semaglutide — the same drug as standard Wegovy but at a higher weekly maintenance dose. The FDA approved it in March 2026 for adults who need more weight loss than 2.4 mg provides.
In the Phase 3b STEP UP trial, semaglutide 7.2 mg produced 20.7% mean body weight loss over 72 weeks — about six points more than the 2.4 mg dose in the same study. Around 31% of patients lost 25% or more of their body weight.
No. You titrate up from the standard 0.25 mg starting dose through the usual ladder to 2.4 mg, then continue escalating to 7.2 mg under your prescriber's guidance. Starting high increases gastrointestinal side effects.
Same molecule (semaglutide), same weekly injection — the difference is the maintenance dose: 7.2 mg instead of 2.4 mg. Wegovy HD is meant for people who need more weight loss or have plateaued on 2.4 mg.
They are different drugs. Wegovy HD is high-dose semaglutide (GLP-1 only); Zepbound is tirzepatide (GLP-1 + GIP). Both reach into the ~20%+ weight-loss range. Choice depends on tolerance, insurance, and your prescriber's judgment.
Use the free Shotlee app to log your weekly 7.2 mg injection, weight, side effects, and titration history. Reminders keep your weekly dose on schedule.
Track Wegovy HD in Shotlee
Free weekly-dose logging, titration history, weight trends, and side-effect tracking for your 7.2 mg protocol.